Skip to content
lifestyle.easyhouseremodeling.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BridgeBio Pharma, Inc.
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
March 23, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 13, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
March 11, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
March 10, 2026
BridgeBio to Participate in March Investor Conferences
March 10, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 9, 2026
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
March 9, 2026
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
March 8, 2026
CORRECTING and REPLACING — BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 27, 2026
←
Previous Page
1
2
3
4
Next Page
→